WO2005024061A3 - Compounds and methods for modulation of dna replication - Google Patents

Compounds and methods for modulation of dna replication Download PDF

Info

Publication number
WO2005024061A3
WO2005024061A3 PCT/GB2004/003774 GB2004003774W WO2005024061A3 WO 2005024061 A3 WO2005024061 A3 WO 2005024061A3 GB 2004003774 W GB2004003774 W GB 2004003774W WO 2005024061 A3 WO2005024061 A3 WO 2005024061A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
dna replication
modulation
compounds
assays
Prior art date
Application number
PCT/GB2004/003774
Other languages
French (fr)
Other versions
WO2005024061A2 (en
Inventor
Torsten Krude
Christo Christov
David Szuts
Original Assignee
Cancer Rec Tech Ltd
Torsten Krude
Christo Christov
David Szuts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0320654A external-priority patent/GB0320654D0/en
Priority claimed from GB0406383A external-priority patent/GB0406383D0/en
Application filed by Cancer Rec Tech Ltd, Torsten Krude, Christo Christov, David Szuts filed Critical Cancer Rec Tech Ltd
Publication of WO2005024061A2 publication Critical patent/WO2005024061A2/en
Publication of WO2005024061A3 publication Critical patent/WO2005024061A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Abstract

Molecules and methods for modulating chromosomal DNA replication and cell proliferation and assays to identify agents for modulating chromosomal DNA replication and cell proliferation. The molecules, methods and assays may be used in the treatment of proliferative diseases such as cancer.
PCT/GB2004/003774 2003-09-03 2004-09-02 Compounds and methods for modulation of dna replication WO2005024061A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0320654A GB0320654D0 (en) 2003-09-03 2003-09-03 Compounds and methods for modulation of DNA replication
GB0320654.7 2003-09-03
GB0406383A GB0406383D0 (en) 2004-03-22 2004-03-22 Compounds and methods for modulation of dna replication
GB0406383.0 2004-03-22

Publications (2)

Publication Number Publication Date
WO2005024061A2 WO2005024061A2 (en) 2005-03-17
WO2005024061A3 true WO2005024061A3 (en) 2005-04-28

Family

ID=34276822

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2004/003774 WO2005024061A2 (en) 2003-09-03 2004-09-02 Compounds and methods for modulation of dna replication

Country Status (1)

Country Link
WO (1) WO2005024061A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060068434A1 (en) * 2004-09-21 2006-03-30 Jay Stoerker Methods and compositions for detecting cancer using components of the U2 spliceosomal particle
JPWO2008084319A1 (en) * 2006-12-18 2010-04-30 協和発酵キリン株式会社 New nucleic acid
JP2014513521A (en) * 2011-01-26 2014-06-05 セファイド How to detect lung cancer
WO2015055857A1 (en) * 2013-10-18 2015-04-23 Institut National De La Sante Et De La Recherche Medicale (Inserm) Rny-derived small rnas as biomarkers for atherosclerosis-related disorders
CN110546261B (en) 2017-03-29 2023-07-25 中国医学科学院基础医学研究所 Small RNAs and use thereof for preventing and/or treating fibroproliferative disorders and/or syndromes

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6521405B1 (en) * 1997-09-02 2003-02-18 Cancer Research Campaign Technology Limited Cell-free replication system and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6521405B1 (en) * 1997-09-02 2003-02-18 Cancer Research Campaign Technology Limited Cell-free replication system and uses thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHEN XINGUO ET AL: "Ro ribonucleoproteins contribute to the resistance of Deinococcus radiodurans to ultraviolet irradiation", GENES AND DEVELOPMENT, vol. 14, no. 7, 1 April 2000 (2000-04-01), pages 777 - 782, XP002318586, ISSN: 0890-9369 *
CHEN XINGUO ET AL: "The Ro 60 kDa autoantigen: insights into cellular function and role in autoimmunity", JOURNAL OF MOLECULAR MEDICINE (BERLIN), vol. 82, no. 4, April 2004 (2004-04-01), pages 232 - 239, XP002318588, ISSN: 0946-2716 *
CHEN XINGUO ET AL: "The Ro autoantigen binds misfolded U2 small nuclear RNAs and assists mammalian cell survival after UV irradiation.", CURRENT BIOLOGY, vol. 13, no. 24, 16 December 2003 (2003-12-16), pages 2206 - 2211, XP002318587, ISSN: 0960-9822 *
SZÜTS DÁVID ET AL: "RPA is an initiation factor for human chromosomal DNA replication.", NUCLEIC ACIDS RESEARCH. 15 MAR 2003, vol. 31, no. 6, 15 March 2003 (2003-03-15), pages 1725 - 1734, XP002318585, ISSN: 1362-4962 *

Also Published As

Publication number Publication date
WO2005024061A2 (en) 2005-03-17

Similar Documents

Publication Publication Date Title
WO2004063362A3 (en) Cell cycle progression proteins
WO2007149481A3 (en) Tetrahydro-isoalpha acid based protein kinase modulation cancer treatment
WO2004034990A3 (en) Methods and compositions for use in treating cancer
WO2005005599A3 (en) Modulation of c-reactive protein expression
BRPI0510663A (en) at least one chemical entity, composition, methods for modulating cenp-e kinesin activity, inhibiting cenp-e, and treating a cell proliferative disease, and, use of at least one chemical entity
WO2006122156A3 (en) Compounds for modulating trpv3 function
WO2007056124A3 (en) Compounds for modulating trpv3 function
WO2009009173A3 (en) Klotho-beta for use in treating cancer, liver disorders, gallstones, wasting syndrome and obesity-related diseases
WO2006048777A3 (en) Modified growth hormones
WO2005082341A3 (en) NON-PEPTIDYL AGENTS WITH pHSP20-LIKE ACTIVITY, AND USES THEREOF
WO2004050707A3 (en) Tumor-specific recognition molecules
WO2006097743A3 (en) Method for actvating natural killer cells by tumor cell preparation in vitro
WO2006107854A3 (en) Epidermal growth factor receptor gene copy number
TW200505455A (en) Anti-cancer medicaments
WO2005087951A3 (en) Reagents, methods and kits for use in deactivating nucleic acids
WO2005092073A3 (en) Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation
WO2005085861A3 (en) Nucleic acids and encoded polypeptides for use in liver disorders and epithelial cancer
AU2003226676A1 (en) Methods and compositions for the identification, assessment, and therapy of small cell lung cancer
WO2006050373A3 (en) Methods and compositions for modulating apoptosis
WO2008151819A3 (en) Treatment of tumors using specific anti-l1 antibody
EP1551392A4 (en) Novel lapacho compounds and methods of use thereof
WO2005024061A3 (en) Compounds and methods for modulation of dna replication
WO2009017719A8 (en) Modulators of ccr9 receptor and methods of use thereof
WO2005082357A8 (en) Use of beta-lapachone for treating hematologic tumors
WO2004082610A3 (en) Modulation of hyaluronan and cd44 interaction and uses thereof in treating disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase